Cardinal Capital Management Has $9.55 Million Position in Agilent Technologies, Inc. (NYSE:A)

Cardinal Capital Management raised its position in Agilent Technologies, Inc. (NYSE:A) by 7.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,630 shares of the medical research company’s stock after acquiring an additional 4,544 shares during the quarter. Agilent Technologies makes up about 1.6% of Cardinal Capital Management’s investment portfolio, making the stock its 18th largest holding. Cardinal Capital Management’s holdings in Agilent Technologies were worth $9,550,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Agilent Technologies during the 4th quarter worth about $509,904,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Agilent Technologies by 19.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock worth $1,841,659,000 after buying an additional 2,170,219 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Agilent Technologies by 233.7% during the 4th quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock worth $370,552,000 after buying an additional 1,867,377 shares during the last quarter. Brown Advisory Inc. lifted its stake in shares of Agilent Technologies by 262.1% during the 4th quarter. Brown Advisory Inc. now owns 2,292,929 shares of the medical research company’s stock worth $318,786,000 after buying an additional 1,659,768 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Agilent Technologies by 17.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,255,526 shares of the medical research company’s stock worth $1,146,773,000 after buying an additional 1,519,134 shares during the last quarter.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the sale, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares in the company, valued at $3,274,050. The disclosure for this sale can be found here.

Agilent Technologies Stock Down 1.7 %

Agilent Technologies stock traded down $2.29 on Thursday, hitting $130.80. 1,894,533 shares of the stock traded hands, compared to its average volume of 1,724,621. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. The firm has a market cap of $38.16 billion, a P/E ratio of 30.94, a price-to-earnings-growth ratio of 4.57 and a beta of 1.07. The business’s fifty day simple moving average is $139.66 and its 200 day simple moving average is $138.45. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.19 by $0.03. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.58 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company’s revenue for the quarter was down 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.27 earnings per share. As a group, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.25 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be issued a $0.236 dividend. The ex-dividend date of this dividend is Tuesday, July 2nd. This represents a $0.94 annualized dividend and a yield of 0.72%. Agilent Technologies’s payout ratio is 22.22%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on A shares. Citigroup lowered their price target on shares of Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. UBS Group lowered their price target on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Oppenheimer raised their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Stifel Nicolaus decreased their target price on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a report on Thursday, May 30th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $136.88.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.